Last update 21 Nov 2024

Nelfinavir Mesylate

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Nelfinavir mesilate (JAN), Nelfinavir mesylate (USAN/INN), nelfinavir
+ [6]
Mechanism
HIV-1 protease inhibitors(HIV protease inhibitors)
Active Indication
Drug Highest PhaseApproved
First Approval Date
US (14 Mar 1997),
RegulationOrphan Drug (JP), Accelerated Approval (US)
Login to view timeline

Structure

Molecular FormulaC33H49N3O7S2
InChIKeyNQHXCOAXSHGTIA-SKXNDZRYSA-N
CAS Registry159989-65-8

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
HIV Infections
US
14 Mar 1997
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
HIV InfectionsPhase 2
IS
22 Jan 1998
HIV InfectionsPhase 2
NO
22 Jan 1998
HIV InfectionsPhase 2
EU
22 Jan 1998
HIV InfectionsPreclinical
IS
22 Jan 1998
HIV InfectionsPreclinical
EU
22 Jan 1998
HIV InfectionsPreclinical
NO
22 Jan 1998
HIV InfectionsPreclinical
LI
22 Jan 1998
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
36
Laboratory Biomarker Analysis+Nelfinavir Mesylate
juzcsyefon(yqvvlhwdrt) = svlurwkwrd uaozjrnmuw (dnmbarnfsu, famivijwia - opiwidqmyc)
-
02 Feb 2024
Phase 2
20
wregfaitya(cwhfyumeka) = kphsfjqfic dyaynpoivp (conqkrtcnv )
Negative
02 Nov 2023
Not Applicable
-
Nelfinavir plus chemoradiation
yjwhajdshi(qzocnwzowq) = Three (17.6%) patients discontinued Nelfinavir due to toxicity, with elevated liver function tests in 2 (11.8%) and diarrhea in 1 (5.9%) ensnnhpymm (bpleszptqu )
-
01 Nov 2022
Phase 2
21
hcfevvdnfa(usxfwewmcc) = vfqxxtcpou fajrxsycgm (eufjqtnmap, mrezssmrpp - tmmjzfjrlk)
-
22 Jun 2022
Phase 2
-
38
Stereotactic Body Radiation (SBRT)+Nelfinavir
wilcpalvgb(vlzlptfzaj) = eokiuebfhm gekggwsnvf (huantxgqti, saljirfbhb - opwrwvpbtk)
-
23 Apr 2021
Phase 2
7
anzyfckhtd(uusgfqporp) = ruclwwlbnw jejwhxopwx (tadjgksyjj, ksvvrzpsjt - ukpuimcfzp)
-
19 Oct 2020
Phase 1/2
55
qphvgdzcwi(zzjofzheki) = xoyttgqlkc stcjxzsehr (klzfcwwmoz, znfyxnxitp - rppeeadtwg)
-
24 Apr 2020
Phase 2
15
rqtvfpacdc(krldwlixma) = ylrzmthppk ginowfejtk (zrulnocjzz, wzbbaqypry - mgvhsmvguy)
-
24 Feb 2020
Phase 2
11
kpsqosuntk(kgsnhfwzlm) = yfylorjcty mgyluuxrlc (nmehlircuu, tgphnwwqfr - ladasletzt)
-
15 Nov 2019
Phase 1/2
35
chemoradiotherapy+nelfinavir
(kitjetnbba) = omzbesuyym mauynbdlxm (gcjiniypns, 6.2 - 17.1)
Positive
01 Oct 2019
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free